Posted by Michael Wonder on 04 Oct 2022
Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
4 October 2022 - Approximately half of all patients with metastatic breast cancer express low levels of HER2.
Roche announced today that the US FDA approved the PATHWAY anti-HER2/neu (4B5) tabbit monoclonal primary antibody to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment.
